Deborah K Armstrong

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis
    Deborah K Armstrong
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Oncologist 10:686-94. 2005
  2. pmc A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study
    Deborah K Armstrong
    Johns Hopkins Kimmel Cancer Center, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Gynecol Oncol 105:667-71. 2007
  3. ncbi request reprint Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity
    Deborah K Armstrong
    Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Oncologist 9:33-42. 2004
  4. ncbi request reprint A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
    Deborah K Armstrong
    Assistant Professor, Oncology, Gynecology, and Obstetrics, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Invest New Drugs 21:453-7. 2003
  5. ncbi request reprint A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study
    Deborah K Armstrong
    Sidney Kimmal Comprehensive Cancer Centèr John Hopkins, Baltimore, MD 21231, USA
    Invest New Drugs 21:373-7. 2003
  6. ncbi request reprint Relapsed ovarian cancer: challenges and management strategies for a chronic disease
    Deborah K Armstrong
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Bunting Blaustein Cancer Research Building, Room 190, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Oncologist 7:20-8. 2002
  7. ncbi request reprint Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis
    Robert E Bristow
    The Kelly Gynecologic Oncology Service, Department of Obstetrics and Gynecology, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Gynecol Oncol 106:476-81. 2007
  8. doi request reprint Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer
    Saranya Chumsri
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21231, USA
    Clin Breast Cancer 10:40-5. 2010
  9. ncbi request reprint Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome
    Ritu Salani
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Cancer 109:685-91. 2007
  10. pmc The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study
    Amanda Nickles Fader
    Johns Hopkins Medical Institutions, Baltimore, MD, USA Electronic address
    Gynecol Oncol 132:560-5. 2014

Detail Information

Publications56

  1. ncbi request reprint Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis
    Deborah K Armstrong
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Oncologist 10:686-94. 2005
    ..The risk of grade 3 or 4 anemia was higher during the first four courses of therapy and may need to be more aggressively managed with erythropoietin therapy...
  2. pmc A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study
    Deborah K Armstrong
    Johns Hopkins Kimmel Cancer Center, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Gynecol Oncol 105:667-71. 2007
    ....
  3. ncbi request reprint Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity
    Deborah K Armstrong
    Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Oncologist 9:33-42. 2004
    ..Proposed topotecan dosing guidelines to reduce and manage myelosuppression are outlined...
  4. ncbi request reprint A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
    Deborah K Armstrong
    Assistant Professor, Oncology, Gynecology, and Obstetrics, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Invest New Drugs 21:453-7. 2003
    ....
  5. ncbi request reprint A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study
    Deborah K Armstrong
    Sidney Kimmal Comprehensive Cancer Centèr John Hopkins, Baltimore, MD 21231, USA
    Invest New Drugs 21:373-7. 2003
    ....
  6. ncbi request reprint Relapsed ovarian cancer: challenges and management strategies for a chronic disease
    Deborah K Armstrong
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Bunting Blaustein Cancer Research Building, Room 190, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Oncologist 7:20-8. 2002
    ..This review will discuss these important patient management issues and will conclude with case studies illustrating two distinct treatment strategies (planning and sequencing) for the long-term management of patients with ovarian cancer...
  7. ncbi request reprint Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis
    Robert E Bristow
    The Kelly Gynecologic Oncology Service, Department of Obstetrics and Gynecology, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Gynecol Oncol 106:476-81. 2007
    ..To evaluate the cost-effectiveness of intraperitoneal cisplatin and paclitaxel chemotherapy as front-line treatment for patients with Stage III epithelial ovarian cancer following optimal primary cytoreductive surgery...
  8. doi request reprint Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer
    Saranya Chumsri
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21231, USA
    Clin Breast Cancer 10:40-5. 2010
    ..We evaluated pathologic complete response (pCR) rate and cardiac safety of preoperative doxorubicin and cyclophosphamide followed by a taxane with or without trastuzumab...
  9. ncbi request reprint Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome
    Ritu Salani
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Cancer 109:685-91. 2007
    ....
  10. pmc The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study
    Amanda Nickles Fader
    Johns Hopkins Medical Institutions, Baltimore, MD, USA Electronic address
    Gynecol Oncol 132:560-5. 2014
    ..The study objective was to determine the prognostic significance of serum CA-125 levels in patients with grade 1 serous ovarian carcinoma (SOC) enrolled in a Phase III study...
  11. pmc Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
    Michelle A Rudek
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 1M52, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 139:135-43. 2013
    ..BSA was not the main source of pharmacokinetic variability. Fixed-dose capecitabine is feasible, and simplifies dosing...
  12. pmc A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer
    Michaela J Higgins
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRBI, Room 144, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 131:915-24. 2012
    ..Simvastatin appears to modulate estrone sulfate concentrations and its potential chemopreventive activity in breast cancer warrants further investigation...
  13. ncbi request reprint Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Deborah K Armstrong
    Johns Hopkins Kimmel Cancer Center, Baltimore, USA
    N Engl J Med 354:34-43. 2006
    ..The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer...
  14. ncbi request reprint Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis
    Robert E Bristow
    The Kelly Gynecologic Oncology Service, Department of Obstetrics and Gynecology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Cancer 109:1513-22. 2007
    ..The objective of this study was to evaluate the cost-effectiveness of centralized referral of patients with advanced-stage epithelial ovarian cancer who underwent primary cytoreductive surgery and adjuvant chemotherapy...
  15. ncbi request reprint Recurrent micropapillary serous ovarian carcinoma
    Robert E Bristow
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287 1246, USA
    Cancer 95:791-800. 2002
    ....
  16. ncbi request reprint Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range
    Antonio Santillan
    Kelly Gynecology Oncology Service, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Clin Oncol 23:9338-43. 2005
    ..To evaluate the risk of epithelial ovarian cancer (EOC) recurrence in patients with rising serum cancer antigen 125 (CA-125) levels that remain below the upper limit of normal (< 35 U/mL)...
  17. doi request reprint Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
    Deborah K Armstrong
    Medical Oncology, Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA
    Gynecol Oncol 129:452-8. 2013
    ..We evaluated clinical activity of farletuzumab, alone and combined with chemotherapy, in women with first-relapse, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancers...
  18. ncbi request reprint Salvage cytoreductive surgery for recurrent endometrial cancer
    Robert E Bristow
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA
    Gynecol Oncol 103:281-7. 2006
    ..To determine the survival impact of salvage cytoreductive surgery, and other prognostic variables, among patients with recurrent endometrial cancer...
  19. doi request reprint Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes
    Robert E Bristow
    The Kelly Gynecologic Oncology Service, Departments of Gynecology and Obstetrics and Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps 281, Baltimore, MD 21287, USA
    Gynecol Oncol 115:334-8. 2009
    ..To evaluate the impact of surgeon and hospital case volume, and other related variables, on short-term outcomes after surgery for ovarian cancer...
  20. doi request reprint Analysis of contemporary trends in access to high-volume ovarian cancer surgical care
    Robert E Bristow
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Ann Surg Oncol 16:3422-30. 2009
    ..However, contemporary patterns of primary surgical care for ovarian cancer according to hospital and surgeon case volume remain poorly defined...
  21. ncbi request reprint A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 9:5922-8. 2003
    ..This study evaluated the activity of the first-generation analog DENSpm in women with metastatic breast cancer...
  22. ncbi request reprint Abdominal carcinomatosis in women with a history of breast cancer
    Ruchi Garg
    Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, 600 N Wolfe Street, Baltimore, MD 21287 1281, USA
    Gynecol Oncol 99:65-70. 2005
    ....
  23. ncbi request reprint Micropapillary serous ovarian carcinoma: surgical management and clinical outcome
    Robert E Bristow
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Gynecol Oncol 86:163-70. 2002
    ....
  24. ncbi request reprint New issues in systemic therapy for ovarian cancer
    Deborah K Armstrong
    Oncology, Gynecology and Obstetrics at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    J Natl Compr Canc Netw 11:690-3. 2013
    ..Deborah K. Armstrong reviewed findings supporting intraperitoneal chemotherapy, the use of bevacizumab, the use of neoadjuvant chemotherapy, and the potential of poly (ADP-ribose) polymerase (PARP) inhibitors and other newer agents...
  25. ncbi request reprint Clinical significance of Her-2/neu overexpression in uterine serous carcinoma
    Teresa P Diaz-Montes
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Gynecol Oncol 100:139-44. 2006
    ..To evaluate the clinico-pathologic characteristics and survival outcome associated with overexpression of Her-2/neu in patients with uterine serous carcinoma (USC)...
  26. pmc Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer
    Aditya Bardia
    Breast Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building 1, Room 144, 1650 Orleans Street, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 131:907-14. 2012
    ..Physicians should weigh competing risks and offer early screening and cardiac prevention strategies for women at a greater risk for CVD...
  27. ncbi request reprint Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?
    Tatiana M Prowell
    Breast Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231, USA
    Semin Oncol 33:681-7. 2006
    ..At this writing, HER-2/neu expression should not influence the decision to use endocrine therapy...
  28. pmc A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors
    Ting Bao
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 20201, USA
    Breast Cancer Res Treat 138:167-74. 2013
    ..As sham acupuncture used in this study may not be equivalent to placebo, further studies with a non-acupuncture arm may be required to establish whether acupuncture is beneficial for the treatment of AIMSS...
  29. pmc Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer
    Richard C Zellars
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins, 401 N Broadway, Suite 1440, Baltimore, MD 21231, USA
    J Clin Oncol 27:2816-22. 2009
    ..We hypothesized that anthracycline-based chemotherapy and concurrent partial breast irradiation (PBI) is safe and conducted a single-arm feasibility trial testing this hypothesis with dose-dense doxorubicin and cyclophosphamide (ddAC)...
  30. pmc Recent progress in the diagnosis and treatment of ovarian cancer
    Danijela Jelovac
    Department of Oncology, The Johns Hopkins Kimmel Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    CA Cancer J Clin 61:183-203. 2011
    ....
  31. ncbi request reprint Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time
    Deborah K Armstrong
    Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA
    J Clin Oncol 24:4531-3. 2006
  32. ncbi request reprint A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study
    Deborah K Armstrong
    John Hopkins Kimmel Cancer Center, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Gynecol Oncol 103:391-6. 2006
    ..The goals of this phase I study were to determine the maximum tolerated dose (MTD) of IP paclitaxel microspheres and the pharmacology of paclitaxel after IP paclitaxel microsphere administration...
  33. pmc Survival in women with grade 1 serous ovarian carcinoma
    Amanda Nickles Fader
    Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Obstet Gynecol 122:225-32. 2013
    ..To examine clinicopathologic variables associated with survival among women with low-grade (grade 1) serous ovarian carcinoma enrolled in a phase III study...
  34. pmc Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics
    Nwabundo Nwankwo
    Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Invest New Drugs 31:653-60. 2013
    ..Given distinct mechanism of actions of enzastaurin and bevacizumab, preclinical studies suggest enhanced antitumor activity in combination. This phase I study assessed the combination's safety and efficacy...
  35. doi request reprint Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
    Charles M Rudin
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, David H Koch Cancer Research Building, Room 544, 1550 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 26:1119-27. 2008
    ..To assess the pharmacogenomic and pharmacokinetic determinants of skin rash and diarrhea, the two primary dose-limiting toxicities of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib...
  36. ncbi request reprint Surgical care of elderly women with ovarian cancer: a population-based perspective
    Teresa P Diaz-Montes
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Gynecol Oncol 99:352-7. 2005
    ..To characterize the primary surgical care and short-term outcomes for ovarian cancer in women aged 80 years and older compared to women younger than 80 years...
  37. ncbi request reprint A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer
    Leisha A Emens
    Johns Hopkins Oncology Center, Baltimore, MD, USA
    Breast Cancer Res Treat 76:145-56. 2002
    ..Our aims were to determine the maximum tolerated dose (MTD) of 5-FU in the dose-dense regimen and to determine the impact of dose-dense chemotherapy on HDC/PBSCT...
  38. ncbi request reprint Emerging therapeutic options for platinum-sensitive ovarian cancer patients
    Deborah K Armstrong
    Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Clin Adv Hematol Oncol 9:1-16. 2011
    ..Several recent and ongoing clinical trials involving these investigational agents are described. Throughout, the experts discuss the implication of these findings in the clinical setting...
  39. pmc Role of farletuzumab in epithelial ovarian carcinoma
    Danijela Jelovac
    The Johns Hopkins Kimmel Cancer Center, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 190, Baltimore, MD 21231, USA
    Curr Pharm Des 18:3812-5. 2012
    ..A second trial of farletuzumab with carboplatin and taxane in platinum-sensitive EOC in first relapse is slated to complete accrual in early 2012. Results from these trials will help define the role of farletuzumab in EOC...
  40. ncbi request reprint Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis
    Robert E Bristow
    Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD 21287 1248, USA
    J Clin Oncol 20:1248-59. 2002
    ..To evaluate the relative effect of percent maximal cytoreductive surgery and other prognostic variables on survival among cohorts of patients with advanced-stage ovarian carcinoma treated with platinum-based chemotherapy...
  41. ncbi request reprint Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors
    Wells A Messersmith
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:1270-5. 2006
    ..Preclinical studies have shown synergy between bortezomib and taxanes. We conducted a phase I study combining bortezomib and docetaxel in refractory solid tumor patients...
  42. pmc Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole
    Tatiana M Prowell
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Prev Res (Phila) 4:1993-2001. 2011
    ....
  43. pmc Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats
    Allison C Sharrow
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Ovarian Res 3:9. 2010
    ..Limited progress has been made toward improving the survival rate of patients with this disease in part because of the lack of a good animal model. We present here a model of spontaneous ovarian carcinoma arising in a normal Lewis rat...
  44. ncbi request reprint Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study
    Charles W Whitney
    Christiana Care Health System, Newark, DE 19713, USA
    Gynecol Oncol 92:4-9. 2004
    ..The objectives of this study were to estimate the clinical response rate and toxicity of daily tamoxifen combined with intermittent weekly medroxyprogesterone acetate (MPA)...
  45. ncbi request reprint Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group
    Stephen D Williams
    Indiana University Cancer Center, 535 Barnhill Drive, Indianapolis, IN 46202, USA
    Gynecol Oncol 95:496-9. 2004
    ..This study was designed to evaluate the effect of adjuvant chemotherapy with carboplatin and etoposide in patients with completely resected stage IB-III dysgerminoma...
  46. ncbi request reprint Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study
    Joan L Walker
    Department of Obstetrics and Gynecology, University of Oklahoma, PO Box 26901, Oklahoma City, OK 73190, USA
    Gynecol Oncol 100:27-32. 2006
    ..To evaluate reasons for discontinuing intraperitoneal (IP) chemotherapy, and to compare characteristics of patients who did versus did not successfully complete six cycles of IP chemotherapy...
  47. ncbi request reprint Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study
    Lari B Wenzel
    College of Medicine, University of California at Irvine, Irvine, CA, USA
    J Clin Oncol 25:437-43. 2007
    ..The purpose of this report is to comprehensively evaluate the patient-reported outcomes associated with IP versus IV therapy...
  48. ncbi request reprint A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
    Kathleen N Moore
    University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd WP 2470, Oklahoma City, OK 73014, and Washington University Barnes Jewish Christian Hospitals, St Louis, MO, USA
    Gynecol Oncol 105:299-303. 2007
    ..The objective of this study was to compare response rate and survival in patients with cervical cancer treated with PT or CT...
  49. ncbi request reprint Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study
    Constance D Lehman
    Department of Radiology, University of Washington Medical Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, G3 200, Seattle, WA 98109 1023, USA
    Radiology 244:381-8. 2007
    ..To prospectively determine cancer yield, callback and biopsy rates, and positive predictive value (PPV) of mammography, magnetic resonance (MR) imaging, and ultrasonography (US) in women at high risk for breast cancer...
  50. ncbi request reprint Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
    William E Winter
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brooke Army Medical Center, Ft Sam
    J Clin Oncol 25:3621-7. 2007
    ..The purpose of this study was to identify factors predictive of poor prognosis in a similarly treated population of women with advanced EOC...
  51. pmc Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    Department of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Gynecol Oncol 108:493-9. 2008
    ..This phase II trial assessed the activity and tolerability of cetuximab (C225, Erbitux) in combination with carboplatin in patients with relapsed platinum-sensitive ovarian or primary peritoneal carcinoma...
  52. pmc Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study
    Lari Wenzel
    University of California, Irvine, Irvine, CA 92697, USA
    Gynecol Oncol 110:60-4. 2008
    ..To evaluate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Abdominal Discomfort (FACT/GOG-AD) subscale for assessing abdominal discomfort in patients undergoing treatment for ovarian cancer...
  53. pmc Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 26:4144-50. 2008
    ..To determine the cost effectiveness of intraperitoneal versus intravenous regimens for adjuvant treatment of optimally resected stage III ovarian cancer...
  54. ncbi request reprint Breast cancer risk reduction
    Therese B Bevers
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw 5:676-701. 2007
  55. ncbi request reprint Ovarian cancer. Clinical practice guidelines in oncology
    Robert J Morgan
    City of Hope Cancer Center, USA
    J Natl Compr Canc Netw 4:912-39. 2006
  56. ncbi request reprint Optic neuropathy from metastatic squamous cell carcinoma of the cervix: an unusual CNS presentation
    Chia Chiao Portera
    Department of Internal Medicine, Sinai Hospital of Baltimore, MD 21215, USA
    Gynecol Oncol 102:121-3. 2006
    ..Central nervous system (CNS) metastases from cervical carcinoma are uncommon events. Leptomeningeal involvement from cervical squamous cell carcinoma has not been extensively described...